summit trial tirzepatide results 60-Second Journal Club: The examined cardiovascular outcomes of treatment with in patients with heart failure with preserved ejection fraction and obesity. Read the full trial A comparison of the effects

Tirzepatide patients lost an average of 1.1% more lean body mass after three months and 2% after 12 months of continuous use, the analysis by Massachusetts-based data analytics firm nference found

2021;23(10):e24336

8, 2023, the FDA approved Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors

Between 2021 and 2023, 800 randomly selected participants across 37 countries received once-weekly injections of either semaglutide or a placebo, the press release stated

Here is what to gather: The prescribed testosterone vial A 3 mL syringe A larger 18-gauge (18G) drawing needle, used to draw the medication into the syringe (testosterone is thick and needs a wider needle for this step) A smaller injection needle, typically 2225 gauge, 11.5 inches for intramuscular injections

Real-world data shows that roughly 40-50% of requests for branded GLP-1 coverage face initial denial or require step therapy, meaning patients often wait weeks before approval or must absorb out-of-pocket costs upfront